Lineage Cell Therapeutics Q2 revenue falls but posts profit

Lineage Cell Therapeutics

06/08/2026 21:11

Overview
US cell therapy developer's Q2 revenue declined yr/yr due to lower collaboration revenue
Q2 net income reached $1.5 mln, reversing a loss from the prior year period
Operating expenses fell sharply, reflecting absence of prior year impairment charge

Outlook
Lineage expects cash and equivalents to support operations into Q3 2028
Company expects initial preclinical data from COR1 program in 2026
Company continues to advance multiple clinical and preclinical cell therapy programs

Result Drivers
COLLABORATION REVENUE DECLINE - Co said lower Q2 revenue was mainly due to reduced collaboration revenue recognized from deferred revenues under the Roche Agreement and the prior year termination of the VAC platform-related collaboration
OPERATING EXPENSES DROP - Co attributed lower operating expenses to the absence of last year's $14.8 mln non-cash impairment expense related to the VAC platform
WARRANT LIABILITY REMEASUREMENT - Co said net income was helped by a favorable quarterly fair value remeasurement of warrant liabilities driven by a decrease in share price

Company press release: ID:nBw53FYJfa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
 
$1.54 mln
 
Q2 Income from Operations
 
-$8.92 mln
 
Q2 Operating Expenses
 
$9.99 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Lineage Cell Therapeutics Inc is $4.50, about 294.7% above its August 5 closing price of $1.14

Reuters Recommended Reads
Aug 6 - Intellia Therapeutics Q2 collaboration revenue falls, net loss widens
Aug 6 - Precision BioSciences Q2 net loss widens on warrant liability charge
Aug 6 - Cartesian Therapeutics Q2 net income steady

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)